Prifemilast - Newsoara Biopharma
Alternative Names: HPP-737; HY-1999Latest Information Update: 22 Sep 2026
At a glance
- Originator vTv Therapeutics LLC
- Developer cAMPfield Therapeutics; Newsoara Biopharma; vTv Therapeutics LLC
- Class Anti-inflammatories; Antipsoriatics; Skin disorder therapies; Small molecules
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Atopic dermatitis; Chronic obstructive pulmonary disease; Plaque psoriasis
- Phase II Crohn's disease; Ulcerative colitis